The Colorado Center for Personalized Medicine (CCPM) is currently returning CYP2C19 genotype results to CCPM Biobank participants. In order to receive a CCPM Biobank pharmacogenetic test result, a participant must sign a consent form agreeing that results can be placed in his or her electronic health record (EHR). After this consent form is signed, results for only a participant’s CYP2C19 genotype will be placed into a participant’s EHR and sent to him or her via UCHealth’s My Health Connection patient portal (if results are available for the participant). Other pharmacogenetic test results will be released in a step-wise approach. Please check back frequently for updates.
No. However, CCPM has embedded clinical decision support (CDS) tools into UCHealth’s EHR to notify clinicians of gene-drug interactions at the time of prescribing. As of December 2020, clinical decision support is available for ten drug-gene pairs affected by variation in CYP2C19.
Please note that not all medications are metabolized by CYP2C19. For medications that are metabolized by CYP2C19, CYP2C19 genotype does not impact outcomes for all medications to the same extent, or does so in an indication-specific manner.
For further information, please visit Biobank Resources located on the Provider Portal on The Source (UCHealth).
For general information about CYP2C19, click here.
The CCPM Biobank pharmacogenetic (PGx) test provides valuable insight into how a patient may respond to certain medications. Below is an example of what this report looks like in the electronic health record with detailed explanations of each area of the report.